FKnol.com

Financial Knowledge & Information Portal

Gilead Sciences (GILD) Company Profile

Updated Sep 9, 2019
Gilead Sciences has the following business profile:
Company's Full Name:Gilead Sciences
Short Name:Gilead Sciences
Trading Ticker Symbol:GILD
Primary Exchange:NASDAQ
Headquarter City/Country:Foster City, California
Primary Industry Sector:Health Care
Seconday Sub-sector:Biotech Biological Products
Main Business Areas: Health Care, Biotech Biological Products, Biotech Products, Major Drug Manufacturers, NASDAQ
Dividend Payments:Dividend History

Market and Trading Information for Gilead Sciences

The following details were available for trading and market data about the stock of Gilead Sciences as of writing:
Current Share Price:$66.33
Previous Year's Closing Price:$62.55
Percentage Price Change (YTD):6.04%
Market Cap:$82.35 billion
52-week Price Range:$60.32 - $79.61
Dividend Per Share:$2.4
EPS (TTM):4.61
Price-Earnings (Trailing):14.38
Price-Earnings (Forward):9.52

Company Profile and Business Description for Gilead Sciences

Gilead Sciences, Inc., incorporated on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products include AmBisome, Atripla, Cayston, Complera/Eviplera, Descovy, Emtriva, Epclusa, Genvoya, Harvoni, Hepsera, Letairis, Odefsey, Ranexa, Sovaldi, Stribild, Truvada, Tybost, Vemlidy, Viread, Vitekta and Zydelig. The Company's areas of focus include HIV; liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection; hematology/oncology; cardiovascular, and inflammation/respiratory diseases. The Company had operations in more than 30 countries, as of December 31, 2016.

Human Immunodeficiency Virus

The Company focuses on HIV patients to choose a single-tablet regimen that allows them to adhere to a fully suppressive course for the management of the disease. Its tenofovir alafenamide (TAF) is a targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than 0.1% that of the Company's Viread (tenofovir disoproxil fumarate (TDF)), as well as improvement in surrogate laboratory markers of renal and bone safety as compared to TDF in clinical trials in combination with other antiretroviral agents. Its TAF-based single-tablet regimens include Genvoya (elvitegravir 150 milligrams (mg)/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) and Odefsey for the treatment of HIV. The Company's products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Emtriva, Tybost and Vitekta.

Descovy is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age or older. Odefsey is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Genvoya is an oral formulation dosed once a day for the treatment of HIV-1 infection in adults. Genvoya is a single-tablet regimen for the treatment of HIV and is a fixed-dose combination of its antiretroviral medicines, Vitekta (elvitegravir), Tybost (cobicistat), Emtriva and TAF. Stribild (elvitegravir/cobicistat/emtricitabine/TDF) is an oral formulation dosed once a day for the treatment of HIV-1 infection in treatment-naive adults. Stribild is a single-tablet regimen for the treatment of HIV and is a fixed-dose combination of its antiretroviral medications, Vitekta, Tybost, Viread and Emtriva. Complera/Eviplera (emtricitabine/rilpivirine/TDF) is an oral formulation dosed once a day for the treatment of HIV-1 infection in adults. Atripla (efavirenz/emtricitabine/TDF) is an oral formulation dosed once a day for the treatment of HIV infection in adults. Atripla is a single-tablet regimen for HIV intended as a stand-alone therapy or in combination with other antiretrovirals.

Truvada (emtricitabine/TDF) is an oral formulation dosed once a day as part of combination therapy to treat HIV infection in adults. It is a fixed-dose combination of its antiretroviral medications, Viread and Emtriva. Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in patients two years of age and older. Emtriva is an oral formulation of a nucleoside analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. In the United States and Europe, Emtriva is also available as an oral solution approved as part of combination therapy to treat HIV infection in children. Tybost is a pharmacokinetic enhancer dosed once a day that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir and darunavir as part of antiretroviral combination therapy in adults with HIV-1 infection. Vitekta is an oral formulation of an integrase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults without known mutations associated with resistance to elvitegravir, the active ingredient of Vitekta. Vitekta is indicated for use as part of HIV treatment regimens that include a ritonavir-boosted protease inhibitor.

Liver Diseases

The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. Vemlidy is an oral formulation of a once-daily treatment of TAF for adults with HBV infection with compensated liver disease. Epclusa is an oral formulation of sofosbuvir and velpatasvir and the first pan-genotypic, single-tablet regimen for the treatment of adults with genotype 1-6 chronic infection. Epclusa is also the first single-tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for ribavirin. Harvoni is an oral formulation of ledipasvir and sofosbuvir dosed once a day for the treatment of genotypes 1, 4, 5 and 6, HCV/HIV-1 co-infection, HCV genotype 1 and 4 liver transplant recipients, and genotype 1-infected patients with decompensated cirrhosis. In Europe, Harvoni is also indicated for certain patients with HCV genotype 4 infection, HCV genotype 3 infection with cirrhosis and/or prior treatment failure and those with HCV/HIV-1 co-infection.

Sovaldi is an oral formulation of sofosbuvir dosed once a day for the treatment of HCV as a component of a combination antiviral treatment regimen. Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day for the treatment of HBV in adults with compensated and decompensated liver disease. Hepsera (adefovir dipivoxil) is an oral formulation of a nucleotide analog polymerase inhibitor, dosed once a day to treat HBV in patients 12 years of age and older.

Hematology/Oncology

The Company offers Zydelig to patients with hematology/oncology diseases. Zydelig (idelalisib) is a Phosphoinositide 3-Kinase (PI3K) delta inhibitor for the treatment of certain blood cancers.

Cardiovascular

The Company's products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Letairis (ambrisentan) is an oral formulation of an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization (WHO) Group 1) in patients with WHO Class II or III symptoms. Ranexa (ranolazine) is an extended-release tablet for the treatment of chronic angina. Lexiscan (regadenoson) injection is indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

Inflammation/Respiratory

The Company's products include Cayston and Tamiflu. Cayston (aztreonam for inhalation solution) is an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients seven years of age and older with Pseudomonas aeruginosa (P. aeruginosa). Tamiflu (oseltamivir phosphate) is an oral antiviral available in capsule form for the treatment and prevention of influenza A and B.

Other

The Company also offers products, including AmBisome and Macugen. AmBisome (amphotericin B liposome for injection) is a liposomal formulation of amphotericin B, an antifungal agent to treat invasive fungal infections caused by various fungal species in adults. Macugen (pegaptanib sodium injection) is an intravitreal injection of an anti-angiogenic oligonucleotide for the treatment of neovascular age-related macular degeneration.

The Company competes with ViiV Healthcare, AbbVie Inc., AbbVie, Merck & Co. Inc., Bristol-Myers Squibb Company, Janssen Therapeutics, Novartis Pharmaceuticals Corporation (Novartis), Actelion Pharmaceuticals US, Inc., United Therapeutics Corporation, Pfizer, Pharmacyclics, Inc., Roche Group, Cephalon, Inc., GSK, Enzon Pharmaceuticals, Inc., Zeneus Pharma Ltd., Three Rivers Pharmaceuticals, LLC and Genpharma, S.A.

333 LAKESIDE DR

Peer / Competitor Companies of Biotech Biological Products Sector

Along with Gilead Sciences, the following other peer (competitor) companies also exist within the same Biotech Biological Products - Health Care sector whose company profile and dividend history is as follows:

▶ Acceleron Pharma (XLRN): Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare ....See Detailed Company Profile  and Dividend History.

▶ Acorda Therapeutics (ACOR): Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. ....See Detailed Company Profile  and Dividend History.

▶ Adaptimmune Therapeutics (ADAP): Adaptimmune Therapeutics plc, incorporated on December 03, 2014, is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) ....See Detailed Company Profile  and Dividend History.

▶ ADMA Biologics (ADMA): ADMA Biologics, Inc., incorporated on June 2, 2006, is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious ....See Detailed Company Profile  and Dividend History.

▶ Adverum Biotechnologies (ADVM): Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., incorporated on July 17, 2006, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from ....See Detailed Company Profile  and Dividend History.

▶ Aerie Pharma (AERI): Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients ....See Detailed Company Profile  and Dividend History.

▶ Aevi Genomic Medicine (GNMX): Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., incorporated on January 27, 2000, is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate ....See Detailed Company Profile  and Dividend History.

▶ Agenus (AGEN): Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display,....See Detailed Company Profile  and Dividend History.

▶ Amgen (AMGN): Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. The ....See Detailed Company Profile  and Dividend History.

▶ AmpliPhi Biosciences (APHB): AmpliPhi Biosciences Corporation, incorporated on March 9, 1989, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in ....See Detailed Company Profile  and Dividend History.

▶ Apollo Endosurgery (APEN): Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. It develops and distributes devices for minimally invasive surgica....See Detailed Company Profile  and Dividend History.

▶ Applied Genetic (AGTC): Applied Genetic Technologies Corporation, incorporated on October 24, 2003, is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases ....See Detailed Company Profile  and Dividend History.

▶ Aptose Biosciences (APTO): Aptose Biosciences Inc. (Aptose), incorporated on November 1, 2006, is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and ....See Detailed Company Profile  and Dividend History.

▶ ARIAD Pharma (ARIA): ....See Detailed Company Profile  and Dividend History.

▶ Asterias Biotherapeutics (AST): Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. ....See Detailed Company Profile  and Dividend History.

▶ Atara Biotherapeutics (ATRA): Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates ....See Detailed Company Profile  and Dividend History.

▶ aTyr Pharma (LIFE): aTyr Pharma, Inc., incorporated on October 8, 2005, is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, ....See Detailed Company Profile  and Dividend History.

▶ Audentes Therapeutics (BOLD): Audentes Therapeutics, Inc., incorporated on November 13, 2012, is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening ....See Detailed Company Profile  and Dividend History.

▶ AveXis (AVXS): AveXis, Inc., incorporated on March 10, 2010, is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic ....See Detailed Company Profile  and Dividend History.

▶ Aviragen Therapeutics (AVIR): Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., incorporated on March 14, 1969, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The ....See Detailed Company Profile  and Dividend History.

... See Full List of All Stocks of Biotech Biological Products Sector.

Stock List of Other Health Care Sub-sectors

▶ Stocks of Sector

▶ Stocks of Biotech Sector

▶ Stocks of Biotech Apparatus Sector

▶ Stocks of Biotech Diagnostics Sector

▶ Stocks of Biotech Products Sector

▶ Stocks of Biotech Research Sector

▶ Stocks of Drug Delivery Sector

▶ Stocks of Drug Development Sector

▶ Stocks of Drug Manufacturer Sector

▶ Stocks of Health Care Sector

▶ Stocks of Health Care Equipment and Services Sector

▶ Stocks of Hospital and Nursing Management Sector

▶ Stocks of Industrial Specialties Sector

▶ Stocks of Major Pharmaceuticals Sector

▶ Stocks of Medical Dental Instruments Sector

▶ Stocks of Medical Electronics Sector

▶ Stocks of Medical Nursing Services Sector

▶ Stocks of Medical Products Sector

▶ Stocks of Medical Specialities Sector

▶ Stocks of Ophthalmic Goods Sector

▶ Stocks of Other Pharmaceuticals Sector

▶ Stocks of Precision Instruments Sector


Stock List of Other Top-level Sectors

▶ Stocks of Sector

▶ Stocks of Basic Industries Sector

▶ Stocks of Basic Materials Sector

▶ Stocks of Capital Goods Sector

▶ Stocks of Communication Services Sector

▶ Stocks of Consumer Cyclical Sector

▶ Stocks of Consumer Defensive Sector

▶ Stocks of Consumer Durables Sector

▶ Stocks of Consumer Non-Durables Sector

▶ Stocks of Consumer Services Sector

▶ Stocks of Energy Sector

▶ Stocks of Finance Sector

▶ Stocks of Financial Services Sector

▶ Stocks of Health Care Sector

▶ Stocks of Industrials Sector

▶ Stocks of Miscellaneous Sector

▶ Stocks of Public Utilities Sector

▶ Stocks of Real Estate Sector

▶ Stocks of Services Sector

▶ Stocks of Technology Sector

▶ Stocks of Transportation Sector

▶ Stocks of Utilities Sector